Acromegaly screening: Difference between revisions

Jump to navigation Jump to search
 
(2 intermediate revisions by 2 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
There is insufficient evidence to recommend routine screening for acromegaly.


== Screening ==
== Screening ==
*According to the endocrine society, screening for acromegaly by measurement of IGF-1 is recommended among patients with the clinical features of acromegaly. These features include the following:<ref name="pmid25356808">{{cite journal| author=Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A et al.| title=Acromegaly: an endocrine society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 11 | pages= 3933-51 | pmid=25356808 | doi=10.1210/jc.2014-2700 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25356808  }} </ref>
There is insufficient evidence to recommend routine screening for acromegaly.  
**Enlarged hands and feet
**Change in the facial features
**Headache
**Increase sweating
**Paraesthesia
**Skin thickening
**Protrusion of the lower jaw
*Screening also is recommended in patients with associated conditions of acromegaly. Acromegaly is associated with different comorbidities so that screening is important in patients with these comorbidities which include:
**Diabetes Mellitus
**Carpal tunnel syndrome
**Arthritis
**Sleep apnea
**Hypertension


==References==
==References==

Latest revision as of 15:59, 26 October 2017